HIV vaccines for prevention of infection and disease in humans (Q34122331)

31 July 2017

1 reference

title

HIV vaccines for prevention of infection and disease in humans (English)

1 reference

31 July 2017

main subject

prevention of HIV/AIDS

0 references

author name string

Dolin R

series ordinal

1 reference

31 July 2017

publication date

1 December 2000

1 reference

Infectious Disease Clinics of North America

31 July 2017

published in

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

31 July 2017

page(s)

1001-1016

1 reference

The expression of hybrid HIV:Ty virus-like particles in yeast

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Phase I/II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Intracellular Neutralization of HIV Transcytosis across Tight Epithelial Barriers by Anti-HIV Envelope Protein dIgA or IgM

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

In vivo migration and function of transferred HIV-1-specific cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Core structure of gp41 from the HIV envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Macromolecular assemblage in the design of a synthetic AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

The simian immunodeficiency viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Human Studies in the Development of Human Immunodeficiency Virus Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Identification and biologic characterization of an acutely lethal variant of simian immunodeficiency virus from sooty mangabeys (SIV/SMM).

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Quantitation of HIV-1-Specific IgG, IgA, and IgM Antibodies in Human Genital Tract Secretions

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Measuring vaccine-induced HIV neutralization: report of a workshop.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Expression of AIDS virus envelope gene in recombinant vaccinia viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

DNA vaccines: safety and efficacy issues

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Progress in the development of an HIV-1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Utility of SHIV for testing HIV-1 vaccine candidates in macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine — HGP-30-KLH

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Applications of pox virus vectors to vaccination: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

A role for carbohydrates in immune evasion in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Attenuated HIV vaccine: caveats.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Highly attenuated poxvirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

NYVAC: a highly attenuated strain of vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Immune and hematopoietic parameters in HIV‐1‐infected chimpanzees during clinical progression toward AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Annual updated survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Preclinical AIDS vaccine development: Formal survey of global HIV, SIV, and SHIV in vivo challenge studies in vaccinated nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Atomic structure of the ectodomain from HIV-1 gp41

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

The antigenic structure of the HIV gp120 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970144-6

7 January 2021

10.1016/S0891-5520(05)70144-6

Identifiers

DOI

1 reference

31 July 2017

1 reference